Bayer AG Gross Profit vs. Current Valuation

BAYN Stock  EUR 19.79  0.19  0.97%   
Considering the key profitability indicators obtained from Bayer AG's historical financial statements, Bayer AG NA may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Bayer AG's ability to earn profits and add value for shareholders.
For Bayer AG profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bayer AG to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bayer AG NA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bayer AG's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bayer AG NA over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Bayer AG's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bayer AG is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bayer AG's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bayer AG NA Current Valuation vs. Gross Profit Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bayer AG's current stock value. Our valuation model uses many indicators to compare Bayer AG value to that of its competitors to determine the firm's financial worth.
Bayer AG NA is number one stock in gross profit category among its peers. It also is the top company in current valuation category among its peers reporting about  3.10  of Current Valuation per Gross Profit. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bayer AG's earnings, one of the primary drivers of an investment's value.

Bayer Current Valuation vs. Gross Profit

Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Bayer AG

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
27.04 B
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Bayer AG

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
83.74 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Bayer Current Valuation vs Competition

Bayer AG NA is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers—General industry is currently estimated at about 95.34 Billion. Bayer AG totals roughly 83.74 Billion in current valuation claiming about 88% of equities under Drug Manufacturers—General industry.

Bayer AG Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bayer AG, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bayer AG will eventually generate negative long term returns. The profitability progress is the general direction of Bayer AG's change in net profit over the period of time. It can combine multiple indicators of Bayer AG, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. BAYER AG is traded on Frankfurt Stock Exchange in Germany.

Bayer Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bayer AG. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bayer AG position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bayer AG's important profitability drivers and their relationship over time.

Use Bayer AG in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bayer AG position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bayer AG will appreciate offsetting losses from the drop in the long position's value.

Bayer AG Pair Trading

Bayer AG NA Pair Trading Analysis

The ability to find closely correlated positions to Bayer AG could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bayer AG when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bayer AG - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bayer AG NA to buy it.
The correlation of Bayer AG is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bayer AG moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bayer AG NA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bayer AG can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Bayer AG position

In addition to having Bayer AG in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Agency Mbs ETFs Thematic Idea Now

Agency Mbs ETFs
Agency Mbs ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Agency Mbs ETFs theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agency Mbs ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Bayer Stock

To fully project Bayer AG's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Bayer AG NA at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Bayer AG's income statement, its balance sheet, and the statement of cash flows.
Potential Bayer AG investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Bayer AG investors may work on each financial statement separately, they are all related. The changes in Bayer AG's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Bayer AG's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.